Core Viewpoint - The announcement details the expiration of reserved rights under the 2024 Restricted Stock Incentive Plan due to the failure to identify incentive targets within the stipulated timeframe [1][3]. Group 1: Approval Process - The 2024 Restricted Stock Incentive Plan has undergone necessary approval procedures, including resolutions passed by the Supervisory Board and the Board of Directors [2]. - The plan was publicly disclosed, and no objections were raised during the public notice period [1][2]. Group 2: Reserved Rights Status - According to the regulations, the reserved grant portion must identify incentive targets within 12 months post-approval; otherwise, the reserved rights will expire [3]. - As of the announcement date, 335,000 shares of the second category of restricted stock have had their reserved rights expire due to the failure to identify incentive targets within the required timeframe [3]. Group 3: Impact of Expiration - The expiration of these reserved rights will not affect the company's capital structure, financial status, or operational results significantly [3]. - The management team is expected to continue fulfilling their responsibilities to create value for all shareholders [3].

证券代码：301382 证券简称：蜂助手 公告编号：2025-056 蜂助手股份有限公司 关于2024年限制性股票激励计划预留权益失效的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、2024年限制性股票激励计划已履行的相关审批程序 1、2024年6月12日，公司分别召开了第三届董事会第二十二次会议、第三届 监事会第十五次会议，审议并通过《关于公司<2024年限制性股票激励计划（草 案）>及摘要的议案》、《关于公司<2024年限制性股票激励计划实施考核管理 办法>的议案》、《关于提请股东大会授权董事会办理2024年限制性股票激励计 划有关事项的议案》。 2、公司对授予的激励对象名单的姓名和职务在公司内部进行了公示，公示 期为自2024年6月13日起至2024年6月22日止。在公示期内，公司监事会收到了部 分员工希望成为授予激励对象的诉求，并根据相关法规进行了解释和说明。截至 公示期满，未收到对公司2024年限制性股票激励计划（以下简称"本激励计划"） 拟激励对象提出的其他异议。并于2024年6月24日披露了《监事会关于公司2024 年限制性股票激励计 ...

根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第9 号——回购股份》等相关规定，公司应当在每个月的前三个交易日内披露截至上月 末的回购进展情况。现将公司上月末回购进展的具体情况公告如下： 证券代码：301382 证券简称：蜂助手 公告编号：2025-057 蜂助手股份有限公司 关于回购股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、回购股份的基本情况 蜂助手股份有限公司（以下简称"公司"）于2025年1月13日召开了第四届董 事会第三次会议，审议通过了《关于回购公司股份方案的议案》，同意以公司银行 专项贷款资金、自有资金和/或自筹资金通过集中竞价交易方式回购公司已发行的 部分人民币普通股（A股）股票，本次回购股份将全部用于实施股权激励计划或员 工持股计划。公司拟用于本次回购的资金总额不低于人民币2,500万元且不超过人 民币5,000万元（均含本数），回购的价格不超过人民币42元/股（含本数），具体 回购股份的数量和金额以回购期满时实际回购的股份数量和金额为准。回购期限为 自公司董事会审议通过回购股份方案之日起不超过12个 ...

Group 1 - The company currently has no specific plans to apply for licenses related to virtual asset trading [1]

北京大成（广州）律师事务所 关于蜂助手股份有限公司 2025 年第一次临时股东大会的 法律意见书 www.dentons.cn 广州市珠江新城珠江东路 6 号广州周大福金融中心 14 层、15 层 Tel.: 86 20 8527 7000/01 Fax: 86 20 8527 7002 北京大成（广州）律师事务所 关于蜂助手股份有限公司 2025 年第一次临时股东大会的法律意见书 致：蜂助手股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公司 股东会规则（2025 年修订）》（以下简称"《股东会规则》"）等法律、法规和其 他有关规范性文件的要求，北京大成（广州）律师事务所（以下简称"本所"）接 受蜂助手股份有限公司（以下简称"公司"）的委托，指派律师参加公司 2025 年 第一次临时股东大会（以下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集程序、召开程序、出席会议人员 资格、召集人资格、表决程序及表决结果发表法律意见，并不对本次股东大会所审 议的议案、议案所涉及的数字及内容发表意见。 ...

证券代码：301382 证券简称：蜂助手 公告编号：2025-054 蜂助手股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示: 1、本次股东大会无否决或变更议案的情况。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： （1）现场会议日期和时间：2025年6月30日（星期一）下午14:30 （2）网络投票日期和时间：2025 年 6 月 30 日 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年6月30 日9:15-9:25、9:30-11:30、13:00-15:00；通过深圳证券交易所互联网投票系统 投票的具体时间为：2025年6月30日9:15至15:00期间的任意时间。 2、召开地点：广东省广州市天河区黄埔大道660号汇金国际金融中心10楼6 号会议室。 3、召开方式：本次股东大会采用现场表决与网络投票相结合的方式召开。 4、召集人：公司第四届董事会。 5、主持人：董事长罗洪鹏先生。 6、本次会议的召集、召开符合《中 ...

证券代码：301382 证券简称：蜂助手 公告编号：2025-055 蜂助手股份有限公司 关于减少注册资本暨通知债权人公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 蜂助手股份有限公司（以下简称"公司"）于2025年6月11日召开了第四届董 事会第六次会议，审议通过了《关于2024年限制性股票激励计划首次授予部分第一 个解除限售期解除限售条件未成就、第一个归属期归属条件未成就、回购注销及作 废部分限制性股票相关事项的议案》，2025年6月30日，公司召开了2025年第一次 临时股东大会，审议通过了上述议案。详细内容详见公司于2025年6月12日在巨潮 资讯网（www.cninfo.com.cn）披露的《第四届董事会第六次会议决议公告》（公 告编号：2025-049）、《关于2024年限制性股票激励计划首次授予部分第一个解除 限售期解除限售条件未成就、第一个归属期归属条件未成就、回购注销及作废部分 限制性股票相关事项的公告》（公告编号：2025-047）。 鉴于公司第一类限制性股票第一个解除限售期因2024年度业绩考核目标未达成 不能解除限售，公司股东大会 ...

证券代码：301382 证券简称：蜂助手 公告编号：2025- 053 蜂助手股份有限公司 关于持股 5%以上股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （二）股东股份累计质押情况 截至公告披露日，公司股东海峡创新所持股份累计质押情况如下： | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 情况 | | 情况 | | | | 持股数 | 持 | 累计质 | 占其 | 占公 | | | | | | 股东 | 量 | 股 | 押股份 | 所持 | 司总 | 已质押股 | | 未质押 | | | 名称 | （股） | 比 | 数量 | 股份 | 股本 | 份限售和 | 占已质 | 股份限 | 占未质 | | | | 例 | （股） | 比例 | 比例 | 冻结、标 | 押股份 | 售和冻 | 押股份 | | | | | | | | 记数量 | 比例 | 结数量 | 比 ...

Investment Rating - Industry rating: Recommended [5] Core Insights - The beauty sector experienced a stable conclusion during the 618 shopping festival, with significant changes in platform and brand dynamics driven by reduced commission policies and interest-based content ecosystems [1][2] - The total GMV for beauty products across four major e-commerce platforms (Taobao, JD, Douyin, Kuaishou) during the 618 period was between 600-700 billion yuan, reflecting a year-on-year growth of over 10% [1] - Taobao maintained the largest market share at 41.3%, followed by Douyin at 35.7%, JD at 14.8%, and Kuaishou at 8.2% [1][13] Summary by Sections E-commerce Platform Dynamics - Douyin's beauty segment is rapidly growing, supported by merchant subsidies and interest-driven consumer engagement, achieving double-digit growth [2] - Douyin's promotional strategies included a 1.4 billion yuan subsidy for merchants in May, with individual merchant reductions reaching up to 2.99 million yuan [2] Skincare and Makeup Categories - In the skincare category, domestic brands like Proya and Han Shu led the market, maintaining their top positions on Taobao and Douyin [3] - The top five brands in the skincare category on Taobao remained stable, with Proya and Han Shu continuing to dominate [3] - In the makeup and fragrance category, new domestic brands are emerging, with Ti Luo Wei achieving rapid growth by focusing on base makeup products [4] International and Domestic Brand Strategies - International brands are performing well due to localized marketing strategies and a willingness to engage with local consumers [8] - Domestic brands are expected to break out of the competitive cycle focused on ingredients and efficacy, emphasizing brand influence and comprehensive user experience [8] Investment Recommendations - Focus on domestic companies with strong brand equity and comprehensive channel strategies, particularly Proya and Han Shu [9] - Highlight technology-driven skincare brands like Betaini and Juzi Biology that target specific consumer needs [9] - Consider daily chemical brands with strong cost-performance ratios and excellent management of emerging channels, such as Runben and Dengkang [9]

Core Insights - The Ministry of Industry and Information Technology and the National Development and Reform Commission have initiated a program to cultivate over 20 pilot platforms for biomanufacturing by 2027, aiming to facilitate industrial scale-up [1] - Significant technological breakthroughs and industrial layouts are emerging in the biomanufacturing sector, with advancements in areas such as polysulfone plastic recycling and wool sterol synthesis [1] - The synergy between policy support and industrial development is accelerating the transition of biomanufacturing from laboratory research to large-scale industrialization, showcasing a vibrant development chain of "technological breakthroughs - policy support - capital influx" [1] Industry Developments - Synthetic biology is reshaping production models in biomanufacturing, enabling tasks that traditional biotechnologies cannot achieve, while also providing more efficient and environmentally friendly biosynthesis solutions [1] - Companies like Huaxi Biological and Yikole are extending their capabilities in synthetic biology, with Huaxi focusing on the supply chain of hyaluronic acid and Yikole leveraging CRISPR-Cas9 technology for precise gene editing [2][3] - The integration of synthetic biology with traditional industries is seen as a means to enhance productivity and create new growth opportunities, rather than a conflict [4] Technological Innovations - Companies are developing comprehensive systems in synthetic biology, focusing on tool, platform, and product integration, with significant advancements in production efficiency [3] - AI is playing a crucial role in enhancing research efficiency in synthetic biology, with companies establishing AI teams to optimize data collection and algorithm development [7] - The use of AI in the design and testing phases of synthetic biology is expected to significantly reduce research timelines and costs, improving overall productivity [7] Market Trends - The biomanufacturing industry is experiencing a wave of policy support, with various local governments implementing initiatives to promote the industrialization of synthetic biology [8] - The market for biomanufacturing in China is projected to approach 1.8 trillion yuan by 2030, indicating substantial growth potential [8] - Recent financing trends show an acceleration in investments in domestic synthetic biology companies, with nearly a hundred firms securing new funding at the beginning of 2025 [8] Future Outlook - The synthetic biology sector is anticipated to undergo rapid technological iterations and deeper application expansions in the next 3-5 years, driven by AI advancements [9] - Companies are encouraged to focus on quality improvement and original design rather than mere scale expansion, to avoid resource wastage and industry chaos [9] - The industry is expected to face dual challenges in technology transfer and industrialization, particularly in constructing microbial cell factories and overcoming engineering challenges in fermentation and purification [10]